Target type: biologicalprocess
Any process that activates or increases the rate or extent of lymphocyte proliferation. [GOC:ai]
Positive regulation of lymphocyte proliferation is a complex biological process that ensures the controlled expansion of lymphocytes, a key component of the adaptive immune system. This process is essential for mounting effective immune responses against pathogens and maintaining immune homeostasis. It involves a cascade of signaling events initiated by various stimuli, such as antigen recognition by T cell receptors or B cell receptors, cytokines, and costimulatory molecules.
Here's a detailed breakdown of the process:
1. **Antigen Recognition:** Lymphocytes, specifically T cells and B cells, recognize specific antigens presented by antigen-presenting cells (APCs) through their respective receptors. T cell receptors (TCRs) on T cells recognize antigen peptides presented by MHC molecules on APCs, while B cell receptors (BCRs) on B cells directly recognize intact antigens.
2. **Signal Transduction:** Antigen recognition triggers a cascade of intracellular signaling pathways. In T cells, TCR engagement leads to the activation of the TCR complex, which recruits and activates kinases such as ZAP-70 and Lck. These kinases initiate downstream signaling pathways that activate transcription factors, such as NF-κB and AP-1. In B cells, BCR engagement activates similar signaling pathways involving Syk and PLCγ2, leading to the activation of transcription factors like NF-κB and NFAT.
3. **Cytokine Production:** Activated lymphocytes release cytokines, which are signaling molecules that promote cell proliferation and differentiation. Key cytokines involved in lymphocyte proliferation include:
* **IL-2:** A key growth factor for T cells.
* **IL-4:** Promotes B cell proliferation and differentiation into antibody-producing plasma cells.
* **IL-6:** Supports proliferation and differentiation of both T and B cells.
4. **Costimulatory Signals:** Along with antigen recognition, lymphocytes require costimulatory signals to become fully activated and proliferate. These signals are provided by interactions between costimulatory molecules on the surface of lymphocytes and their ligands on APCs. Examples include CD28 on T cells binding to CD80/CD86 on APCs and CD40 on B cells binding to CD40 ligand on T cells.
5. **Cell Cycle Progression:** Upon receiving appropriate signals, lymphocytes enter the cell cycle and begin to proliferate. This involves a series of checkpoints that ensure proper DNA replication and cell division. Key molecules involved in cell cycle regulation include cyclins, cyclin-dependent kinases (CDKs), and checkpoint proteins.
6. **Differentiation:** As lymphocytes proliferate, they undergo differentiation into effector cells that are specialized to perform specific immune functions. T cells differentiate into cytotoxic T cells (CTLs) that kill infected cells or helper T cells (Th cells) that release cytokines to support other immune cells. B cells differentiate into plasma cells that produce antibodies.
7. **Regulation:** The positive regulation of lymphocyte proliferation is tightly controlled to prevent excessive immune activation and autoimmune reactions. This regulation is achieved through various mechanisms, including:
* **Apoptosis:** Programmed cell death eliminates activated lymphocytes after they have fulfilled their function.
* **Immune checkpoints:** Molecules that inhibit lymphocyte activation and proliferation, such as CTLA-4 and PD-1.
* **Regulatory T cells (Tregs):** A specialized subset of T cells that suppress the activity of other immune cells.
In conclusion, the positive regulation of lymphocyte proliferation is a complex and highly regulated process that ensures the controlled expansion of these essential immune cells, enabling the body to mount effective immune responses while maintaining immune homeostasis.'
"
Protein | Definition | Taxonomy |
---|---|---|
Thrombopoietin receptor | A thrombopoietin receptor that is encoded in the genome of human. [PRO:WCB, UniProtKB:P40238] | Homo sapiens (human) |
Substance-P receptor | A substance-P receptor that is encoded in the genome of human. [PRO:WCB, UniProtKB:P25103] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
astemizole | astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position. Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects. | benzimidazoles; piperidines | anti-allergic agent; anticoronaviral agent; H1-receptor antagonist |
calmagite | calmagite: indicator used to measure free magnesium &/or calcium in biological systems; structure | ||
clotrimazole | conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes | antiinfective agent; environmental contaminant; xenobiotic | |
econazole | 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 4-chlorobenzyl group. econazole : A racemate composed of equimolar amounts of (R)- and (S)-econazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. Econazole: An imidazole derivative that is commonly used as a topical antifungal agent. | dichlorobenzene; ether; imidazoles; monochlorobenzenes | |
miconazole | 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 2,4-dichlorobenzyl group. miconazole : A racemate composed of equimolar amounts of (R)- and (S)-miconazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes. Miconazole: An imidazole antifungal agent that is used topically and by intravenous infusion. | dichlorobenzene; ether; imidazoles | |
substance p | peptide | neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent | |
paroxetine | paroxetine : A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo. Paroxetine: A serotonin uptake inhibitor that is effective in the treatment of depression. | aromatic ether; benzodioxoles; organofluorine compound; piperidines | antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor |
calconcarboxylic acid | |||
phenylalanylphenylalanylamide | |||
cp 96345 | CP 96345: structure given in first source; potent nonpeptide antagonist of the substance P (NK1) receptor; CP 96344 is enantiomer of CP 96345 | ||
sr 48968 | SR 48968: structure given in first source; neurokinin A antagonist; tachykinin receptor antagonist; SR 48965 is the inactive R-enantiomer of SR 48968 | ||
7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one | 7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one: structure given in first source; RP 68651 is the inactive (3aS,7aS)-isomer; substance P antagonist | ||
senktide | |||
(2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine | (2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine: structure given in first source | ||
l 703606 | L 703606: structure given in first source | ||
3,5-bis(trifluoromethyl)benzyl n-acetyltryptophan | 3,5-bis(trifluoromethyl)benzyl N-acetyltryptophan: structure given in first source; substance P and neurokinin receptor antagonist | ||
l 733060 | 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine: RN given refers to (2S-cis)-isomer; L-733,061 is pharmacologically inactive; structure in first source | piperidines | |
win 64821 | WIN 64821: a dimerized Trp-Phe condensate; structurally similar to verticillins and chaetocins; a nonpeptide neurokinin antagonist; structure given in first source; substance P antagonist | ||
substance p, pro(9)- | substance P, Pro(9)-: RN given refers to the (L-Pro)-isomer; RN for cpd without isomeric designation not available 3/91 | ||
substance p, sar(9)-met(o2)(11)- | substance P, Sar(9)-Met(O2)(11)-: a neurokinin-1 receptor agonist | ||
ranatachykinin a | ranatachykinin A: a tachykinin in frog (Rana catesbeiana) brain and intestine | ||
sr 142806 | |||
tamoxifen | stilbenoid; tertiary amino compound | angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator | |
cp 99994 | 3-(2-methoxybenzylamino)-2-phenylpiperidine: selective NK(1) receptor antagonist; CP-100263 is the inactive enantiomer | ||
neurokinin a | Neurokinin A: A mammalian neuropeptide of 10 amino acids that belongs to the tachykinin family. It is similar in structure and action to SUBSTANCE P and NEUROKININ B with the ability to excite neurons, dilate blood vessels, and contract smooth muscles, such as those in the BRONCHI. | ||
neurokinin b | Neurokinin B: A mammalian neuropeptide of 10 amino acids that belongs to the tachykinin family. It is similar in structure and action to SUBSTANCE P and NEUROKININ A with the ability to excite neurons, dilate blood vessels, and contract smooth muscles, such as those in the URINARY BLADDER and UTERUS. | polypeptide | |
sb 223412 | SB 223412: SB-223412 is the (S)-(-)-isomer; RN given for (S)-isomer; structure in first source | ||
seglitide | seglitide: more potent than somatostatin for inhibition of insulin, glucagon & growth hormone release; used experimentally in treatment of Alzheimer's disease; somatostatin receptor antagonist | ||
biphalin | biphalin: enkephalin dimer; two fragments of Ala(2)-enkephalin are connected by a diamine bridge to form above cpd; structure given in first source | ||
netupitant | netupitant : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoic acid with the secondary amino group of N-methyl-4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-amine; an antiemetic used in combination with palonosetron hydrochloride (under the trade name Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy. netupitant: orally active neurokinin-1 receptor antagonist | aminopyridine; monocarboxylic acid amide; N-alkylpiperazine; N-arylpiperazine; organofluorine compound; toluenes | antiemetic; neurokinin-1 receptor antagonist |
sb 222200 | quinolines | ||
sb 218795 | SB 218795: structure in first source | quinolines | |
substance p (6-11), tyr(6)-d-phe(7)-d-his(9)- | substance P (6-11), Tyr(6)-D-Phe(7)-D-His(9)-: substance P antagonist | ||
vofopitant | |||
pd 154075 | PD 154075: a non-peptide tachykinin NK1 receptor antagonist; structure given in first source | ||
edotecarin | |||
(2s,3s)-2-phenyl-3-((5-trifluoromethoxy-2-methoxy)benzylamino)piperidine | (2S,3S)-2-phenyl-3-((5-trifluoromethoxy-2-methoxy)benzylamino)piperidine: structure given in first source | ||
vestipitant | |||
ly 306740 | LY 306740: LY-307679 is the inactive enantiomer | ||
sdz nkt 343 | SDZ NKT 343: structure in first source | ||
orvepitant | |||
zd 6021 | ZD 6021: structure in first source | ||
tak 637 | TAK 637: structure in first source | ||
casopitant | piperidines | ||
nkp 608 | |||
dnk 333 | DNK 333: a dual neurokinin NK1/NK2 receptor antagonist; structure in first source | ||
4-n-butyl-1-(4-(2-methylphenyl)-4-oxo-1-butyl)-piperidine hydrogen chloride | |||
rolapitant | azaspiro compound; ether; organofluorine compound; piperidines; pyrrolidin-2-ones | antiemetic; neurokinin-1 receptor antagonist | |
spiroquinazoline | spiroquinazoline: isolated from the fungus Aspergillus flavipes; structure given in first source; substance P antagonist | ||
ditryptophenaline | ditryptophenaline: structure in first source | ||
serlopitant | |||
nitd 609 | NITD 609: an antimalarial and coccidiostat; structure in first source | ||
lusutrombopag | lusutrombopag: a thrombopoietin receptor agonist; structure in first source | cinnamic acids | |
aprepitant | aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING. | (trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles | antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist |
l 742694 | L 742694: a neurokinin-1 receptor antagonist; structure given in first source | ||
amg531 |